Recursion Pharmaceuticals Inc (RXRX) — Financial Flexibility Index
Recursion Pharmaceuticals Inc (RXRX) has a Financial Flexibility Index of -0.26x as of March 2026. Free cash flow of $-80.84 Million (operating CF $-81.10 Million minus capex $258.00K) represents 0% of total liabilities ($314.75 Million). Also explore Recursion Pharmaceuticals Inc (RXRX) equity growth momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Recursion Pharmaceuticals Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Recursion Pharmaceuticals Inc across 7 annual periods. Check strategic asset allocation of Recursion Pharmaceuticals Inc to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Recursion Pharmaceuticals Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Recursion Pharmaceuticals Inc. For the full company profile including market capitalisation, see RXRX market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.06x | $-365.34 Million | $-371.81 Million | $343.26 Million | ▼ -27.5% |
| 2024 | -0.83x | $-345.48 Million | $-359.17 Million | $413.82 Million | ▲ +42.4% |
| 2023 | -1.45x | $-275.82 Million | $-287.78 Million | $190.26 Million | ▼ -576.7% |
| 2022 | -0.21x | $-46.16 Million | $-83.52 Million | $215.48 Million | ▲ +87.8% |
| 2021 | -1.76x | $-118.82 Million | $-158.61 Million | $67.41 Million | ▼ -2201.7% |
| 2020 | -0.08x | $-38.66 Million | $-45.40 Million | $504.87 Million | ▲ +67.5% |
| 2019 | -0.24x | $-53.13 Million | $-57.04 Million | $225.70 Million | — |